- Home
- VSCO vs SRRK Comparison
VSCO vs SRRK Comparison
Compare VSCO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSCO | SRRK |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.9B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VSCO | SRRK |
|---|---|---|
| Price | $65.11 | $44.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $49.70 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 1.5M | 757.3K |
| Earning Date | 03-04-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,230,000,000.00 | N/A |
| Revenue This Year | $6.92 | N/A |
| Revenue Next Year | $3.93 | $21,831.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $13.76 | $22.71 |
| 52 Week High | $66.89 | $49.82 |
Technical Indicators
Market Signals| Indicator | VSCO | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 44.17 |
| Support Level | $53.65 | $42.74 |
| Resistance Level | N/A | $48.79 |
| Average True Range (ATR) | 3.23 | 1.76 |
| MACD | 0.32 | -0.25 |
| Stochastic Oscillator | 97.60 | 8.71 |
Price Performance
Historical ComparisonAbout VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.